Hims & Hers Health (NYSE:HIMS) Trading Down 4.1% After Insider Selling

Key Points

• Shares of Hims & Hers Health fell 4.3% following insider selling, with CEO Andrew Dudum selling 660,000 shares at an average price of $50.58, which decreased his ownership by 22.96%.
• The company's latest earnings report revealed an EPS of $0.17, which missed analyst estimates by $0.01, alongside a revenue of $544.83 million, lower than expected.
• Hims & Hers Health has faced downgrades from analysts, with a current consensus rating of "Hold" and a price target of $39.83 after several firms adjusted their ratings.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) fell 4.1% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $47.36 and last traded at $47.93. 11,177,873 shares traded hands during trading, a decline of 67% from the average session volume of 34,156,691 shares. The stock had previously closed at $49.98.

Specifically, insider Soleil Boughton sold 2,572 shares of the business's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $51.64, for a total transaction of $132,818.08. Following the sale, the insider owned 153,021 shares in the company, valued at approximately $7,902,004.44. The trade was a 1.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the business's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the sale, the chief executive officer owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their position. The disclosure for this sale can be found here. In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the sale, the insider owned 169,940 shares in the company, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. UBS Group set a $30.00 price objective on Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of "Hold" and an average target price of $39.83.

Hims & Hers Health Stock Down 0.3%

The business has a fifty day moving average of $53.39 and a 200 day moving average of $45.30. The stock has a market cap of $10.70 billion, a price-to-earnings ratio of 59.93, a P/E/G ratio of 3.16 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same quarter in the prior year, the company posted $0.06 EPS. The company's quarterly revenue was up 72.6% on a year-over-year basis. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. Quaker Wealth Management LLC bought a new stake in Hims & Hers Health during the second quarter worth approximately $29,000. Bessemer Group Inc. boosted its position in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after purchasing an additional 312 shares during the period. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health during the first quarter worth approximately $30,000. UMB Bank n.a. boosted its position in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Hims & Hers Health during the first quarter worth approximately $41,000. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.